Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25325512 | 0.84 | SLC9A1 (0.43) | — | |
| SCHEMBL25326718 | 0.83 | GPR119 (0.48) | PDE4BGPR119KDM4EALOX5APFEN1 | |
| SCHEMBL25301602 | 0.83 | NR1H2 (0.47) | PDE4BGPR119NR1H2NR1H3 | |
| SCHEMBL23091747 | 0.81 | NAMPT (0.51) | PDE4BGPR119KDM4ENR1H2 | |
| SCHEMBL31638083 | 0.80 | GPR119 (0.57) | GPR119NR1H2NR1H3 | |
| SCHEMBL1763904 | 0.77 | SLC9A1 (0.54) | GPR119KDM4E | |
| SCHEMBL21381911 | 0.75 | PDE4B (0.49) | PDE4BKDM4ENR1H2 | |
| SCHEMBL30149865 | 0.75 | PDE4B (0.49) | PDE4BKDM4ENR1H2 | |
| SCHEMBL25325654 | 0.75 | GPR119 (0.47) | PDE4BGPR119KDM4ESTS | |
| SCHEMBL2112595 | 0.74 | GPR119 (0.54) | PDE4BGPR119KDM4ESTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | PDE4B 856/4885GPR119 1935/4885KDM4E 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.